Liquidia Reports $148.3M in YUTREPIA Sales for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Strong Sales Performance: Liquidia achieved approximately $90.1 million in net product sales for YUTREPIA in Q4 2025, totaling $148.3 million for the full year, reflecting a robust 74% quarter-over-quarter growth that underscores strong market demand and the company's execution capabilities.
- Positive Cash Flow: The company generated over $30 million in positive cash flow during Q4 2025, which not only enhances financial stability but also provides funding for future R&D and market expansion initiatives.
- Significant Prescription Growth: Since its launch in June 2025, YUTREPIA has received more than 2,800 unique patient prescriptions, with over 2,200 patients treated and an 85% conversion rate from prescription to treatment, indicating growing physician confidence and market acceptance.
- Future Development Plans: Liquidia plans to continue investing in clinical development in 2026 to advance YUTREPIA and L606, addressing unmet medical needs and further solidifying its market position in treating pulmonary arterial hypertension and related diseases.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LQDA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.910
Low
31.00
Averages
47.50
High
67.00
Current: 41.910
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
Continue Reading
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
Continue Reading